4/25/2013

Opko Health agreed to purchase Prolor Biotech, an Israel-based biopharmaceutical firm that develops longer-acting versions of approved therapeutic proteins, for around $480 million. "Prolor's drug-product candidates for growth hormone deficiency, hemophilia, obesity and diabetes, along with its broadly applicable technology platforms and efficient research and development center are highly valuable assets that will complement Opkos strategy," Opko Chairman and CEO Phillip Frost said.

Related Summaries